Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1;108(2):610-614.
doi: 10.3324/haematol.2022.281610.

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients

Konstantinos Lemonakis  1 , Love Tatting  2 , Mikael Lisak  3 , Kristina Carlson  4 , Jacob Crafoord  5 , Cecilie H Blimark  3 , Antonio I Santamaria  6 , Stina Wichert  7 , Stig Lenhoff  7 , Markus Hansson  3
Affiliations

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients

Konstantinos Lemonakis et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The impact of daratumumab on mean collected stem cells and rescue use of plerixafor.
See this image and copyright information in PMC

References

    1. Cavo M, Gay F, Beksac M, et al. . Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468. - PubMed
    1. Attal M, Lauwers-Cances V, Hulin C, et al. . Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. - PMC - PubMed
    1. Moreau P, Attal M, Hulin C, et al. . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2019 Jun 14;:]. Lancet. 2019;394(10192):29-38. - PubMed
    1. Voorhees PM, Kaufman JL, Laubach J, et al. . Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. - PMC - PubMed
    1. Giralt S, Costa L, Schriber J, et al. . Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295-308. - PubMed

Publication types

MeSH terms

LinkOut - more resources